ORZORA: OS Results With Maintenance Olaparib in Platinum-Sensitive Relapsed Ovarian Cancer With a BRCA Mutation or Other HRR Mutation

June 3-7, 2022; Chicago, Illinois
In the ORZORA trial, maintenance olaparib showed similar OS outcomes in patients with platinum-sensitive relapsed ovarian cancer regardless of whether patients had a germline or a somatic BRCA mutation or a non-BRCA HRR mutation.
Format: Microsoft PowerPoint (.ppt)
File Size: 141 KB
Released: June 13, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seagen & Genmab

Related Content

Experts review key data for ovarian, endometrial, and cervical cancers from the 2022 SGO, ASCO, ESMO, IGCS, and ESGO meetings, from Clinical Care Options (CCO)

Susana Banerjee, MBBS, MA, PhD, FRCP Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS person default Mansoor Raza Mirza, MD Prof Isabelle Ray-Coquard, MD, PhD Angeles Alvarez Secord, MD, MHSc Ignace Vergote, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 23, 2023 Expired: January 22, 2024

Expert commentary on HRD testing, PARP inhibitor, and quality-of-life studies in rare ovarian cancer from the 2022 ESGO Congress, from Clinical Care Options (CCO)

Prof Isabelle Ray-Coquard, MD, PhD Ignace Vergote, MD, PhD Released: December 2, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

Susana Banerjee, MBBS, MA, PhD, FRCP Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS person default Mansoor Raza Mirza, MD Prof Isabelle Ray-Coquard, MD, PhD Angeles Alvarez Secord, MD, MHSc Ignace Vergote, MD, PhD Released: November 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings